

Revenue	GAAP diluted EPS	Non- GAAP diluted EPS
\$8.6B	\$0.81	\$1.26
+8.4% reported +4.8% organic	+1% Y/Y	+2% Y/Y

Revenue by segment

Cardiovascular \$3.3B ▲ +7.0% Y/Y Organic	Neuroscience \$2.4B ▲ +3.1% Y/Y Organic
Medical Surgical \$2.1B ▲ +2.4% Y/Y Organic	Diabetes \$721M ▲ +7.9% Y/Y Organic

Revenue by geography

United States \$4.2B ▲ +3.5% Y/Y Organic	International \$4.4B ▲ +6.1% Y/Y Organic	
 Affera™ Mapping System	 Sphere-9™ PF and RF Ablation and Mapping Catheter	 LigaSure™ Vessel Sealing Technology
 Inceptiv™ Spinal Cord Stimulator	 Micra™ AV2 and VR2	 MiniMed™ 780G and Simplera Sync™



We delivered another consistent quarter of mid-single digit organic revenue growth, with **broad strength from several innovative product categories**, including Pulsed Field Ablation, Transcatheter Valves, Neuromodulation, Diabetes, and Leadless Pacing. We’re confident and well positioned to accelerate our revenue growth in the second half of our fiscal year, as we make **meaningful progress on our major growth drivers.**

Geoff Martha,
Chairman & CEO

